SAN DIEGO, CA -- (Marketwired) -- 08/10/15 -- NuVasive, Inc.(NASDAQ: NUVA) ("NuVasive or the "Company"), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that management will participate in the following upcoming investor event:
- Canaccord Genuity 35th Annual Growth Conference at the Intercontinental Boston Hotel in Boston, MA on Wednesday, August 12, 2015 at 10:00 a.m. ET / 7:00 a.m. PT.
A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the live webcast.
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. The Company is the third largest player in the $9.0 billion global spine market. NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS was designed to provide safer, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
NuVasive cautions you that statements included in this news release or made during the investor event announced herein that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with the acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products
(including the iGA™ platform), expansion of the Company's network of sales representatives, and the other risks and uncertainties
described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at
. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Source: NuVasive, Inc.